- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00522405
Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma
Background Hepatocellular carcinoma, a malignant tumor of liver is one of the most common cancers worldwide. All India Institute Of Medical Sciences (AIIMS) being a tertiary care hospital receives about two to three cases of Hepatocellular carcinoma (HCC) each day in our Gastroenterology out patient department. Most of these patients present late when the disease is already advanced and no curative therapies can be offered. At this stage, palliative therapy forms the mainstay of treatment. This includes TACE or Oral chemotherapy. Whether oral chemotherapy administered along with TACE potentiates the effect and further prolongs survival, needs to be ascertained. No studies of this kind are available.
This prospective study is therefore designed to address this issue.
Study Overview
Detailed Description
Subjects Consecutive patients of unresectable HCC diagnosed from January 2006 at the liver clinic, AIIMS will be included in the study if they fulfill the following criteria-
Inclusion criteria · Patients above 12 years of age with performance status (PST)score of 0-2
· Unresectable HCC with underlying Child's A/B cirrhosis
· Normal Main portal vein and its branches
- Normal Inferior vena cava
- No history of drug allergy
- Informed written consent of patient.
- Less than 50% involvement of liver by HCC
Exclusión criteria
· Unresectable HCC with underlying Child's C cirrhosis
· Performance status 3-5
· Extrahepatic disease
· Vascular involvement
- Co-morbid illness like coronary artery disease, congestive heart failure, chronic renal failure etc
- Previous history of encephalopathy/ upper gastrointestinal bleed in the last six months
- HCC in a female of child bearing age
Diagnostic criteria
- Cirrhosis of liver- Diagnosis will be founded on the basis of clinical, biochemical and endoscopy findings.
- Hepatocellular carcinoma- when any one of the following is present
- Any two imaging modalities(Ultrasound (US), dual phase CT (DPCT)/ contrast enhanced MRI) showing arterialization of the hepatic mass
- AFP more than 400ng/ml along with arterialisation on one imaging modality (DPCT/ contrast enhanced MRI)
- FNAC
3. Randomization
· Patients will be randomized after the confirmation of diagnosis and obtaining written consent
· Sequences will be generated by the Statistician
· Stratified randomization will be done. Two strata of child's A and B will be made
· Randomization will be done by drawing consecutively numbered opaque sealed envelopes
· Randomization into A (TACE) and B (TACE +oral chemotherapy) will be done.
4. Definitions
Unresectable HCC-
· Liver mass larger than 5cm in diameter (single/ multiple), involving less than 50% of the liver.
· Multiple masses more than three in number and more than 3cm in diameter.
Tumor response
This will be based on Dual phase CT findings
· Complete response (CR)- Tumor fully covered with lipiodol showing no viable tissue
- Partial response (PR)- Tumor partially covered (>75%) by lipiodol
- Mild response (MR)- About 50 to 75% coverage of the tumor by lipiodol
- No response (NR) - About 25 to 50% coverage of the tumor by lipiodol
- Fresh lesions (FL)- Appearance of new mass lesions in the liver with or without recurrence at the site of previous mass
- Patient tolerance- Grade 1: no side effects Grade 2: moderate side effects Grade 3: severe side effects Grade 4: life threatening side effects
Performance status (PST score)
PST score of 0-5 would be assessed on the following basis 0- No cancer related symptoms. Normal life style 1- Minor symptoms related to cancer. Capable of non-strenuous activity. Fully ambulatory 2- Ambulatory and capable of all self care but unable to carry out any work activities Confined to bed less than 50% of waking hours 3- Capable of only limited self care. Confined to bed more than 50% of waking hours.
4- Completely disabled. Cannot carry on any self care. Totally confined to bed. 5- Death
5. Sample Size Systematic review of RCTs for TACE show a 2 year survival of 37%. Expecting that addition of oral drugs would increase survival to 37 to 60%, for a power of 80% and error of 5%, a sample size of 73 patients in each arm would be required (Total 146 patients).
6. Procedure of TACE
· Patient would be admitted a day prior to the procedure
· Patient would be made to fast overnight with intravenous fluid infusion started for maintaining hydration
· Pre-procedure analgesic (3rd generation antibiotic) would be started at a dose of 2gm intravenously, 12 hourly, at least 12 hour before the procedure and continued 5 days post procedure
· Under local anesthesia, the Femoral artery would be punctured at the upper thigh with a Medicut 18 gauge
· A catheter would be introduced through this route with the help of a guide wire and a flush aortogram, superior mesenteric arterioportography and the celiac artery run would be undertaken to define the size and location of the tumors, feeding vessels and to assess the portal vein patency
· Superselective catheterization of the hepatic artery feeding the tumor would be done
· By placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.
· Stable drug mixture would be prepared by using Doxorubicin 50mg, Cisplatin 100mg in combination with 10-15ml of ionic contrast media and 10-20ml of lipiodol by continuously agitating the mixture.
· Hydrocortisone 100mg and augmenting dose of analgesic and sedative would be injected prior to the administration of the drug.
· The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two lever lock syringes connected across a three way.
· Gelfoam particles would be injected following this for embolization
· Post procedure, devascularization would be confirmed by additional angiography of the hepatic artery.
· Procedure would last approx 45mts-1 hour.
· Tight compression would be given at the punctured site and patient would be shifted to the ward once complete hemostasis is achieved.
7. Follow up post TACE Clinical follow up
- All patients would be followed up in the Liver clinic monthly unless their clinical condition warrants earlier follow up
- Liver function tests/ complete blood count would also be done at each visit and AFP (if elevated earlier) every six months
- Patient tolerance, child's status would be estimated. Imaging follow up
- At one month, a dual phase CT would be done to ascertain the response to therapy and the need to repeat the procedure. Subsequently, the DPCT would be done at 3 and 6 monthly intervals.
Once the tumor shows complete coverage, randomization into the two treatment groups would be done
9. Repeat TACE on follow up This would be done if any of the following is noted
- DPCT shows viable tumor
- Fresh lesions appear
Elevated serum AFP occurs with or without appearance of viable mass on DPCT
10. Oral chemotherapy Drugs used would be Thalidomide and Capecitabine in the following dosage schedule-
Thalidomide---100mg once a day (OD) for 7 days, Increased to 200mg OD for 7 days, further increased to 300mgOD for 7 days till a maximum of 600mg once a day is reached
Capecitabine---- 500mg OD for 7 days, then 1000mg OD for next 7 days, increased to a maximum dose of 1500mg OD.
Total leucocyte count & Platelet count would be monitored every 15 days
11. Duration of follow up- Two years after achieving total coverage of the mass lesion on DPCT
12. Outcome measures Following parameters will be used to ascertain the outcome of treatment
Primary Outcome
- Survival rate- calculated from the start of TACE
- End point Group 1 - Progression of disease and repeat TACE is not possible Group 2 - Death
Secondary Outcome
- Tumor response on dual phase CECT
- Patient tolerance
- Childs' status of cirrhosis- will be ascertained at one and two years of follow up depending upon the Childs' scoreScore <6- Childs'A, 7-9 Childs'B and >10 Childs'C
Study Type
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Subrat K Acharya, D.M
- Phone Number: 4934 91-11-26588500
- Email: subratacharya2004@yahoo.com
Study Locations
-
-
Delhi
-
New Delhi, Delhi, India, 110029
- Recruiting
- All India Institute of Medical Sciences
-
Sub-Investigator:
- Sreenivas Vishnubhatla, Ph.D
-
Sub-Investigator:
- Shashi B Paul, Ph.D
-
Sub-Investigator:
- Shivanand Gamanagatti, MD
-
Sub-Investigator:
- Kaushal Madan, DM
-
Sub-Investigator:
- Sreenivasa B Chalamalasetty, DM
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients above 12 years of age with performance status (PST)score of 0-2
- Unresectable HCC with underlying Child's A/B cirrhosis
- Normal Main portal vein and its branches
- Normal Inferior vena cava
- No history of drug allergy
- Informed written consent of patient.
- Less than 50% involvement of liver by HCC
Exclusion Criteria:
- Unresectable HCC with underlying Child's C cirrhosis
- Performance status 3-5
- Extrahepatic disease
- Vascular involvement
- Co-morbid illness like coronary artery disease, congestive heart failure, chronic renal failure etc
- Previous history of encephalopathy/ upper gastrointestinal bleed in the last six months
- HCC in a female of child bearing age
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Transarterial Chemoembolisation
|
|
Active Comparator: 2
TACE Plus oral chemotherapy
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Survival rate- calculated from the start of TACE
|
Secondary Outcome Measures
Outcome Measure |
---|
a) Tumor response on dual phase CECT b) Patient tolerance c) Childs' status of cirrhosis- will be ascertained at one and two years of follow up depending upon the Childs' scoreScore <6- Childs'A, 7-9 Childs'B and >10 Childs'C
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Subrat K Acharya, DM, All India Institute of Medical Sciences, New Delhi, India
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A-39/29.1.2007
- ICMR No-5/8/7/26/99-ECD-I
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
Clinical Trials on TACE
-
Beijing Tsinghua Chang Gung HospitalUnknownHepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)China
-
Beijing Tsinghua Chang Gung HospitalUnknownHuge Hepatocellular Carcinoma (HCC) (≥10cm)China
-
Shanghai Zhongshan HospitalRecruitingA Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCCHepatocellular Carcinoma | DonafenibChina
-
Eastern Hepatobiliary Surgery HospitalCompletedHepatocellular CarcinomaChina
-
Sun Yat-sen UniversityUnknownHepatocellular Carcinoma | Liver CancerChina
-
Sun Yat-sen UniversityUnknownHepatocellular Carcinoma | Liver CancerChina
-
Fudan UniversityUnknownHepatocellular CarcinomaChina
-
Kindai UniversityUnknownCarcinoma, Hepatocellular | Hepatocellular Carcinoma | Liver Neoplasm | Unresectable Hepatocellular CarcinomaJapan
-
Ivy Life Sciences, Co., LtdTri-Service General HospitalUnknownLiver Cancer | HepatoCellular CarcinomaTaiwan
-
Assiut UniversityUnknown